stoxline Quote Chart Rank Option Currency Glossary
Avadel Pharmaceuticals plc (AVDL)
12.53  0.99 (8.58%)    12-01 16:00
Open: 11.36
High: 12.58
Volume: 802,108
Pre. Close: 11.54
Low: 11.36
Market Cap: 1,125(M)
Technical analysis
2023-12-01 4:18:23 PM
Short term     
Mid term     
Targets 6-month :  14.93 1-year :  17.44
Resists First :  12.78 Second :  14.93
Pivot price 11.28
Supports First :  10.75 Second :  9.5
MAs MA(5) :  11.74 MA(20) :  11.2
MA(100) :  12.11 MA(250) :  11.1
MACD MACD :  0.2 Signal :  0.1
%K %D K(14,3) :  70.2 D(3) :  58.3
RSI RSI(14): 64.5
52-week High :  16.85 Low :  5.92
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ AVDL ] has closed above the upper band by 14.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 10.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.71 - 11.76 11.76 - 11.82
Low: 11.27 - 11.33 11.33 - 11.39
Close: 11.44 - 11.54 11.54 - 11.63
Company Description

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Headline News

Fri, 01 Dec 2023
Avadel Pharmaceuticals (AVDL) Shares Cross Above 200 DMA - Nasdaq

Tue, 21 Nov 2023
Institutional investors are Avadel Pharmaceuticals plc's (NASDAQ:AVDL) biggest bettors and were rewarded after last week's US$79m market cap gain - Simply Wall St

Wed, 08 Nov 2023
Avadel Pharmaceuticals Provides Corporate Update and Reports ... - Yahoo Finance

Tue, 07 Nov 2023
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences - Yahoo Finance

Mon, 30 Oct 2023
Avadel Pharmaceuticals to Provide a Corporate Update and Report ... - Yahoo Finance

Mon, 23 Oct 2023
Investors might be losing patience for Avadel Pharmaceuticals' (NASDAQ:AVDL) increasing losses, as stock sheds 9.4% over the past week - Simply Wall St

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers—Specialty & Generic
Shares Out 90 (M)
Shares Float 68 (M)
Held by Insiders 4.9 (%)
Held by Institutions 63.7 (%)
Shares Short 4,000 (K)
Shares Short P.Month 3,800 (K)
Stock Financials
EPS -2.16
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.23
Profit Margin 0 %
Operating Margin -500.6 %
Return on Assets (ttm) -48.8 %
Return on Equity (ttm) -325.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0.09
EBITDA (p.s.) -1.49
Qtrly Earnings Growth 0 %
Operating Cash Flow -116 (M)
Levered Free Cash Flow -65 (M)
Stock Valuations
PE Ratio -5.83
PEG Ratio -0.5
Price to Book value 10.18
Price to Sales 132.23
Price to Cash Flow -9.72
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android